In our analysis, NSCLC tumors with KRAS mutations are associated with a higher frequency of PD-L1 expression (TPS 1 - 49%) compared to other driver mutations, except for BRAF V600E and MET exon 14 skipping mutations, and mutation-dependent associations with TMB (Figures 2C, D; Supplementary Figure S1), consistent with previous findings (22). This evidence concerns the gene KRAS and non-small cell lung carcinoma.